Use of mesalazine in diverticular disease

Francesco Di Mario, Giuseppe Comparato, Libera Fanigliulo, Giovanni Aragona, Lucas G. Cavallaro, Giulia M. Cavestro, Angelo Franzé

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Diverticular disease includes a spectrum of conditions sharing the underlying pathology of acquired diverticula of the colon: symptomatic uncomplicated diverticular disease, recurrent symptomatic uncomplicated diverticular disease, and complicated diverticular disease. Goals of therapy in diverticular disease should be to improve symptoms and to prevent recurrent attacks in symptomatic uncomplicated diverticular disease, and to prevent the complications of disease such as diverticulitis. Inflammation seems to play a key role in all forms of the disease. This is the rationale for the use of anti-inflammatory drugs such as mesalazine. Inflammation in such diseases seems to be generated by a heightened production of proinflammatory cytokines, reduced anti-inflammatory cytokines, and enhanced intramucosal synthesis of nitric oxide. The mechanisms of action of mesalazine are not yet well understood. It is an anti-inflammatory drug that inhibits factors of the inflammatory cascade (such as cyclooxygenase) and free radicals, and has an intrinsic antioxidant effect. Some recent studies confirm the efficacy of mesalazine in diverticular disease both in relief of symptoms in symptomatic uncomplicated forms and in prevention of recurrence of symptoms and main complications.

Original languageEnglish
JournalJournal of Clinical Gastroenterology
Volume40
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Mesalamine
Anti-Inflammatory Agents
Colon Diverticula
Cytokines
Inflammation
Diverticulitis
Prostaglandin-Endoperoxide Synthases
Pharmaceutical Preparations
Free Radicals
Nitric Oxide
Antioxidants
Pathology

Keywords

  • Diverticular diseases
  • Diverticulosis
  • Mesalazine

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Di Mario, F., Comparato, G., Fanigliulo, L., Aragona, G., Cavallaro, L. G., Cavestro, G. M., & Franzé, A. (2006). Use of mesalazine in diverticular disease. Journal of Clinical Gastroenterology, 40(SUPPL. 3). https://doi.org/10.1097/01.mcg.0000225509.98041.4b

Use of mesalazine in diverticular disease. / Di Mario, Francesco; Comparato, Giuseppe; Fanigliulo, Libera; Aragona, Giovanni; Cavallaro, Lucas G.; Cavestro, Giulia M.; Franzé, Angelo.

In: Journal of Clinical Gastroenterology, Vol. 40, No. SUPPL. 3, 08.2006.

Research output: Contribution to journalArticle

Di Mario, F, Comparato, G, Fanigliulo, L, Aragona, G, Cavallaro, LG, Cavestro, GM & Franzé, A 2006, 'Use of mesalazine in diverticular disease', Journal of Clinical Gastroenterology, vol. 40, no. SUPPL. 3. https://doi.org/10.1097/01.mcg.0000225509.98041.4b
Di Mario F, Comparato G, Fanigliulo L, Aragona G, Cavallaro LG, Cavestro GM et al. Use of mesalazine in diverticular disease. Journal of Clinical Gastroenterology. 2006 Aug;40(SUPPL. 3). https://doi.org/10.1097/01.mcg.0000225509.98041.4b
Di Mario, Francesco ; Comparato, Giuseppe ; Fanigliulo, Libera ; Aragona, Giovanni ; Cavallaro, Lucas G. ; Cavestro, Giulia M. ; Franzé, Angelo. / Use of mesalazine in diverticular disease. In: Journal of Clinical Gastroenterology. 2006 ; Vol. 40, No. SUPPL. 3.
@article{467b82cf3f7249e6963d4034024360f4,
title = "Use of mesalazine in diverticular disease",
abstract = "Diverticular disease includes a spectrum of conditions sharing the underlying pathology of acquired diverticula of the colon: symptomatic uncomplicated diverticular disease, recurrent symptomatic uncomplicated diverticular disease, and complicated diverticular disease. Goals of therapy in diverticular disease should be to improve symptoms and to prevent recurrent attacks in symptomatic uncomplicated diverticular disease, and to prevent the complications of disease such as diverticulitis. Inflammation seems to play a key role in all forms of the disease. This is the rationale for the use of anti-inflammatory drugs such as mesalazine. Inflammation in such diseases seems to be generated by a heightened production of proinflammatory cytokines, reduced anti-inflammatory cytokines, and enhanced intramucosal synthesis of nitric oxide. The mechanisms of action of mesalazine are not yet well understood. It is an anti-inflammatory drug that inhibits factors of the inflammatory cascade (such as cyclooxygenase) and free radicals, and has an intrinsic antioxidant effect. Some recent studies confirm the efficacy of mesalazine in diverticular disease both in relief of symptoms in symptomatic uncomplicated forms and in prevention of recurrence of symptoms and main complications.",
keywords = "Diverticular diseases, Diverticulosis, Mesalazine",
author = "{Di Mario}, Francesco and Giuseppe Comparato and Libera Fanigliulo and Giovanni Aragona and Cavallaro, {Lucas G.} and Cavestro, {Giulia M.} and Angelo Franz{\'e}",
year = "2006",
month = "8",
doi = "10.1097/01.mcg.0000225509.98041.4b",
language = "English",
volume = "40",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Use of mesalazine in diverticular disease

AU - Di Mario, Francesco

AU - Comparato, Giuseppe

AU - Fanigliulo, Libera

AU - Aragona, Giovanni

AU - Cavallaro, Lucas G.

AU - Cavestro, Giulia M.

AU - Franzé, Angelo

PY - 2006/8

Y1 - 2006/8

N2 - Diverticular disease includes a spectrum of conditions sharing the underlying pathology of acquired diverticula of the colon: symptomatic uncomplicated diverticular disease, recurrent symptomatic uncomplicated diverticular disease, and complicated diverticular disease. Goals of therapy in diverticular disease should be to improve symptoms and to prevent recurrent attacks in symptomatic uncomplicated diverticular disease, and to prevent the complications of disease such as diverticulitis. Inflammation seems to play a key role in all forms of the disease. This is the rationale for the use of anti-inflammatory drugs such as mesalazine. Inflammation in such diseases seems to be generated by a heightened production of proinflammatory cytokines, reduced anti-inflammatory cytokines, and enhanced intramucosal synthesis of nitric oxide. The mechanisms of action of mesalazine are not yet well understood. It is an anti-inflammatory drug that inhibits factors of the inflammatory cascade (such as cyclooxygenase) and free radicals, and has an intrinsic antioxidant effect. Some recent studies confirm the efficacy of mesalazine in diverticular disease both in relief of symptoms in symptomatic uncomplicated forms and in prevention of recurrence of symptoms and main complications.

AB - Diverticular disease includes a spectrum of conditions sharing the underlying pathology of acquired diverticula of the colon: symptomatic uncomplicated diverticular disease, recurrent symptomatic uncomplicated diverticular disease, and complicated diverticular disease. Goals of therapy in diverticular disease should be to improve symptoms and to prevent recurrent attacks in symptomatic uncomplicated diverticular disease, and to prevent the complications of disease such as diverticulitis. Inflammation seems to play a key role in all forms of the disease. This is the rationale for the use of anti-inflammatory drugs such as mesalazine. Inflammation in such diseases seems to be generated by a heightened production of proinflammatory cytokines, reduced anti-inflammatory cytokines, and enhanced intramucosal synthesis of nitric oxide. The mechanisms of action of mesalazine are not yet well understood. It is an anti-inflammatory drug that inhibits factors of the inflammatory cascade (such as cyclooxygenase) and free radicals, and has an intrinsic antioxidant effect. Some recent studies confirm the efficacy of mesalazine in diverticular disease both in relief of symptoms in symptomatic uncomplicated forms and in prevention of recurrence of symptoms and main complications.

KW - Diverticular diseases

KW - Diverticulosis

KW - Mesalazine

UR - http://www.scopus.com/inward/record.url?scp=33746823297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746823297&partnerID=8YFLogxK

U2 - 10.1097/01.mcg.0000225509.98041.4b

DO - 10.1097/01.mcg.0000225509.98041.4b

M3 - Article

VL - 40

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - SUPPL. 3

ER -